. 2014 Sep 15;35(10):1257–1264. doi: 10.1038/aps.2014.75

Table 1. Effects of liguzinediol on hemodynamic parameters and cardiac function in Dox-treated rats in vivo. Data are expressed as mean±SEM. n=8 in each group. ^cP<0.01 vs control. ^eP<0.05, ^fP<0.01 vs DOX.

	Control	Dox	L 5 mg/kg	L 10 mg/kg	L 20 mg/kg	Dig 0.0225 mg/kg
SBP (mmHg)	99.84±15.92	73.07±17.55^c	77.8±7.10	95.04±13.01^e	90.37±13.28^e	82.42±18.75
DBP (mmHg)	58.11±19.22	51.85±17.97	56.09±8.87	75.36±13.04^f	73.74±11.16^e	62.18±20.38
HR (beat/min)	348.75±50.98	313.88±99.74^c	369.88±36.98	379.00±69.88	403.50±23.09^e	369.63±54.99
+LV dp/dt_max (mmHg/s)	7158.67±1787.06	3256.35±1594.88^c	5004.56±1874.28	5693.05±558.32^f	6502.72±1182.04^f	6270.55±937.01^f
−LV dp/dt_max (mmHg/s)	5731.81±1541.35	2956.25±1396.04^c	4212.46±797.81b	4845.39±764.72^f	5548.26±1289.85^f	4984.65±1060.00^f
LVSP	126.71±14.79	80.54±11.51^c	99.00±8.91^c	110.47±16.25^f	122.80±7.92^f	117.44±14.66^f

SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; LVSP, left ventricular systolic pressure; ±LV dp/dt_max, the maximal rates of increase and decrease of left-ventricle pressure development.

Table 1. Effects of liguzinediol on hemodynamic parameters and cardiac function in Dox-treated rats in vivo. Data are expressed as mean±SEM. n=8 in each group. cP<0.01 vs control. eP<0.05, fP<0.01 vs DOX.

Table 1. Effects of liguzinediol on hemodynamic parameters and cardiac function in Dox-treated rats in vivo. Data are expressed as mean±SEM. n=8 in each group. ^cP<0.01 vs control. ^eP<0.05, ^fP<0.01 vs DOX.